4CNI

Crystal structure of the Fab portion of Olokizumab in complex with IL- 6

Summary for 4CNI

• Entry DOI: 10.2210/pdb4cni/pdb
• Descriptor: OLOKIZUMAB HEAVY CHAIN, FAB PORTION, OLOKIZUMAB LIGHT CHAIN, FAB PORTION, INTERLEUKIN-6, ... (6 entities in total)
• Functional Keywords: immune system, cdp6038, interleukin 6
• Biological source: HOMO SAPIENS (HUMAN); More
• Total number of polymer chains: 6
• Total formula weight: 134590.49

Authors

Shaw, S.,Bourne, T.,Meier, C.,Carrington, B.,Gelinas, R.,Henry, A.,Popplewell, A.,Adams, R.,Baker, T.,Rapecki, S.,Marshall, D.,Neale, H.,Lawson, A. (deposition date: 2014-01-22, release date: 2014-04-30, Last modification date: 2024-10-23)

Primary citation

Shaw, S.,Bourne, T.,Meier, C.,Carrington, B.,Gelinas, R.,Henry, A.,Popplewell, A.,Adams, R.,Baker, T.,Rapecki, S.,Marshall, D.,Moore, A.,Neale, H.,Lawson, A.
Discovery and Characterization of Olokizumab: A Humanized Antibody Targeting Interleukin-6 and Neutralizing Gp130-Signaling.
Mabs, 6:773-, 2014

PubMed Abstract: Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at "Site 3", blocking the interaction with the signaling co-receptor gp130.

PubMed: 24670876
DOI: 10.4161/MABS.28612

Experimental method

X-RAY DIFFRACTION (2.2 Å)